JP7169285B2 - アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用 - Google Patents

アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用 Download PDF

Info

Publication number
JP7169285B2
JP7169285B2 JP2019548652A JP2019548652A JP7169285B2 JP 7169285 B2 JP7169285 B2 JP 7169285B2 JP 2019548652 A JP2019548652 A JP 2019548652A JP 2019548652 A JP2019548652 A JP 2019548652A JP 7169285 B2 JP7169285 B2 JP 7169285B2
Authority
JP
Japan
Prior art keywords
vitamin
parts
pharmaceutical composition
vitamins
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019548652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020509072A (ja
JP2020509072A5 (enExample
Inventor
ズホウ ミングドング
Original Assignee
ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． filed Critical ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー．
Publication of JP2020509072A publication Critical patent/JP2020509072A/ja
Publication of JP2020509072A5 publication Critical patent/JP2020509072A5/ja
Priority to JP2022172956A priority Critical patent/JP2023011769A/ja
Application granted granted Critical
Publication of JP7169285B2 publication Critical patent/JP7169285B2/ja
Priority to JP2024198677A priority patent/JP2025024089A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019548652A 2017-03-07 2018-02-24 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用 Active JP7169285B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022172956A JP2023011769A (ja) 2017-03-07 2022-10-28 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
JP2024198677A JP2025024089A (ja) 2017-03-07 2024-11-14 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710131111.X 2017-03-07
CN201710131111.XA CN108567792A (zh) 2017-03-07 2017-03-07 一种治疗阿尔茨海默病的复合维生素组合物
PCT/CN2018/077107 WO2018161808A1 (zh) 2017-03-07 2018-02-24 维生素组合物在制备用于预防、治疗或延迟阿尔茨海默病的药物中的用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022172956A Division JP2023011769A (ja) 2017-03-07 2022-10-28 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用

Publications (3)

Publication Number Publication Date
JP2020509072A JP2020509072A (ja) 2020-03-26
JP2020509072A5 JP2020509072A5 (enExample) 2021-04-08
JP7169285B2 true JP7169285B2 (ja) 2022-11-10

Family

ID=63448062

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019548652A Active JP7169285B2 (ja) 2017-03-07 2018-02-24 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
JP2022172956A Pending JP2023011769A (ja) 2017-03-07 2022-10-28 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
JP2024198677A Pending JP2025024089A (ja) 2017-03-07 2024-11-14 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022172956A Pending JP2023011769A (ja) 2017-03-07 2022-10-28 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
JP2024198677A Pending JP2025024089A (ja) 2017-03-07 2024-11-14 アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用

Country Status (9)

Country Link
US (2) US11464797B2 (enExample)
EP (2) EP4461361A3 (enExample)
JP (3) JP7169285B2 (enExample)
CN (2) CN108567792A (enExample)
AU (2) AU2018229920B2 (enExample)
BR (1) BR112019018652A2 (enExample)
CA (1) CA3054972A1 (enExample)
ES (1) ES2989651T3 (enExample)
WO (1) WO2018161808A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7442874B2 (ja) * 2019-08-02 2024-03-05 シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド アルツハイマー病における標的としてのｔｐｋの使用
KR102275981B1 (ko) * 2020-03-31 2021-07-13 고려은단주식회사 섬쑥부쟁이 추출물과 비타민 b 복합체의 혼합물을 포함하는 인지기능 개선용 조성물
AU2022464309A1 (en) * 2022-06-22 2025-01-23 Biomedical Research Group Inc. Prophylactic drug and therapeutic drug for diabetes-associated dementia
CN119055674B (zh) * 2024-11-06 2025-02-18 中国医学科学院北京协和医院 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148727A1 (en) 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
JP2009292798A (ja) 2008-06-09 2009-12-17 Masaki Imagawa 認知症を処置するための組成物及びその利用
JP2010531351A (ja) 2007-06-26 2010-09-24 エヌ．ヴィ．ニュートリシア ミニメンタルステート検査２４〜２６点の被験者における記憶力改善
WO2013022139A1 (en) 2011-08-05 2013-02-14 Jae Hoon Moon Method for treatment of diseases caused by accumulation of beta-amyloids in brain parenchyma with low concentration thiazolidinedione derivatives
JP2013526865A (ja) 2010-05-13 2013-06-27 ニトロメガ コーポレーション ニトロ脂肪酸、神経保護および／または認識減退の抑制
JP2014534225A (ja) 2011-10-31 2014-12-18 エヌ．ブイ．・ヌートリシア 認知の改善
JP2015524477A (ja) 2012-08-07 2015-08-24 バック・インスティテュート・フォー・リサーチ・オン・エイジング 神経機能を改善するための多成分製剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626884A (en) 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
DE69930746T2 (de) 1998-06-10 2007-03-15 Crum, Albert B. Vorbeugender und therapeutischer nahrungsmittelzusatz zur schaffung/erhaltung einer die gesundheit schützenden darmmikroflora und zur stärkung des immunsystems
WO2003082339A1 (en) 2002-03-22 2003-10-09 Doc's Guide, Inc. Multivitamin and mineral nutritional supplement
CA2583972A1 (en) 2004-10-14 2006-10-19 Adventures Plus Pty Ltd A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals
US20110275591A1 (en) * 2004-12-01 2011-11-10 Concourse Health Sciences Llc Cocktail for modulation of alzheimer's disease
US9763989B2 (en) * 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
KR20110004691A (ko) * 2009-07-08 2011-01-14 대한민국(농촌진흥청장) 뇌기능 개선효과를 가지는 붉나무 추출물을 포함하는 약학조성물 및 건강식품조성물
EP2554057A4 (en) * 2010-03-31 2013-12-18 Vegenat S A ENERAL OR ORAL FOOD PRODUCT SPECIALLY FOR NUTRITION, PREVENTION AND MITIGATION OF NEUROLOGICAL OR NEURODEGENERATIVE ALTERATIONS OR COGNITIVE DISORDERS
WO2012012682A2 (en) 2010-07-22 2012-01-26 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
BR112014020177A8 (pt) * 2012-03-02 2021-10-19 Nutricia Nv Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada
WO2014026161A1 (en) * 2012-08-10 2014-02-13 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
CN104337813A (zh) 2013-07-23 2015-02-11 上海泽生科技开发有限公司 使用维生素b组合物促进胃肠系统动力的方法
CN104256652A (zh) 2014-10-08 2015-01-07 李明刚 一种口服复合维生素纳米脂质体
CN104922164B (zh) * 2014-12-12 2020-06-02 中国医科大学 一种治疗阿尔茨海默病的药物复合制剂
CN111803514A (zh) * 2015-06-12 2020-10-23 上海泽生科技开发股份有限公司 使用复合维生素b、c组合物促进胃肠系统动力的方法
CN104856048A (zh) 2015-06-18 2015-08-26 安徽医联大成医药科技有限公司 一种促进肠胃蠕动的食品配方及其制备方法
CN108079008A (zh) * 2016-11-23 2018-05-29 上海泽生科技开发股份有限公司 促进胃肠系统动力的复合维生素组合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148727A1 (en) 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
JP2010531351A (ja) 2007-06-26 2010-09-24 エヌ．ヴィ．ニュートリシア ミニメンタルステート検査２４〜２６点の被験者における記憶力改善
JP2009292798A (ja) 2008-06-09 2009-12-17 Masaki Imagawa 認知症を処置するための組成物及びその利用
JP2013526865A (ja) 2010-05-13 2013-06-27 ニトロメガ コーポレーション ニトロ脂肪酸、神経保護および／または認識減退の抑制
WO2013022139A1 (en) 2011-08-05 2013-02-14 Jae Hoon Moon Method for treatment of diseases caused by accumulation of beta-amyloids in brain parenchyma with low concentration thiazolidinedione derivatives
JP2014534225A (ja) 2011-10-31 2014-12-18 エヌ．ブイ．・ヌートリシア 認知の改善
JP2015524477A (ja) 2012-08-07 2015-08-24 バック・インスティテュート・フォー・リサーチ・オン・エイジング 神経機能を改善するための多成分製剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Alzheimer's & Dementia，2010年，Vol. 6，pp. 1-10, 10.e1
Journal of Alzheimer's Disease，2014年，Vol. 31，pp. 225-236
Journal of Alzheimer's Disease，2016年，Vol. 54，pp. 297-306
Nutrition，2015年，Vol. 31，pp. 261-275

Also Published As

Publication number Publication date
JP2020509072A (ja) 2020-03-26
US20200030358A1 (en) 2020-01-30
US20230248756A1 (en) 2023-08-10
JP2023011769A (ja) 2023-01-24
CA3054972A1 (en) 2018-09-13
AU2024202678A1 (en) 2024-05-16
JP2025024089A (ja) 2025-02-19
CN108567792A (zh) 2018-09-25
EP3593805A1 (en) 2020-01-15
US11464797B2 (en) 2022-10-11
BR112019018652A2 (pt) 2020-04-07
CN110520135A (zh) 2019-11-29
ES2989651T3 (es) 2024-11-27
EP4461361A3 (en) 2025-01-01
EP4461361A2 (en) 2024-11-13
EP3593805A4 (en) 2020-10-07
WO2018161808A1 (zh) 2018-09-13
AU2018229920A1 (en) 2019-10-03
AU2018229920B2 (en) 2024-02-08
EP3593805B1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
JP2023011769A (ja) アルツハイマー病を予防し、治療し、又は遅延させるための薬物の調製におけるビタミン組成物の使用
Geisler et al. DNP, mitochondrial uncoupling, and neuroprotection: A little dab'll do ya
CA2766282C (en) Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
Liu et al. Depression-like behaviors in mice subjected to co-treatment of high-fat diet and corticosterone are ameliorated by AICAR and exercise
AU2016238886B2 (en) Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
Al-Jarrah et al. Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease
Ruigrok et al. Effects of early-life stress on peripheral and central mitochondria in male mice across ages
Majolo et al. Recent Drugs Tested in Clinical Trials for Alzheimer´ s and Parkinson´ s Diseases Treatment: Current Approaches in Tracking New Drugs
US20200230118A1 (en) Use of berberine or active metabolite thereof in preparation of drug for preventing and/or treating phenylketonuria
Wei et al. Current situation and challenge of exogenous 3-hydroxybutyrate derived from polyhydroxyalkanoates for elderly health: A review
CN104415023A (zh) 预防或/和治疗胰岛素抵抗及相关病症的组合物
Kolesnyk et al. Current methods of the modeling of experimental diabetes mellitus type 2: a literature review
WO2023236739A1 (zh) 核苷酸混合物在用于防治阿尔茨海默症制剂中的应用
CN104582730B (zh) 一种提高线粒体代谢机能的方法及应用
CN112494509A (zh) 一种防治阿尔茨海默症的组合物及应用
CN114072154A (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
Suyunovich USE OF THE DRUG NEUROVIT
Atabilen et al. Could the ketogenic diet offer hope in management of neurological diseases?
US20220347130A1 (en) Anti-obesity composition containing colchicine and metformin as effective agents
Norwitz Exogenous ketones as a metabolic intervention for Parkinson’s disease
Cao et al. The potential role and mechanism of Rhizoma Coptidis in prevention of diabetic encephalopathy: targeting sodium ion and channels
Escobar et al. Autophagy and aging: diet, exercise, and the link with the target of rapamycin complex 1 (TORC)
Al-Shura Metabolic Disorders and Shen in Integrative Cardiovascular Chinese Medicine: Volume 7
CN120456909A (zh) 用于提高nad水平的组合物及其方法和用途
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221018

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221028

R150 Certificate of patent or registration of utility model

Ref document number: 7169285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250